Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-06-26

Clinical Trial Update: An Open Label Study of Oral Enzastaurin in Participants With Cancer [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of oral enzastaurin in participants with cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neoplasms, Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-06-26